Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Solid Cancer × Nivolumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 33 Carcinoma, Non-Small-Cell Lung 27 Carcinoma, Renal Cell 20 Lung Neoplasms 15 Neoplasm Metastasis 13 Carcinoma, Hepatocellular 13 Pancreatic Neoplasms 9 Colorectal Neoplasms 8 Carcinoma, Transitional Cell 8 Urinary Bladder Neoplasms 7 Squamous Cell Carcinoma of Head and Neck 7 Neoplasms 7 Multiple Myeloma 6 Head and Neck Neoplasms 6 Breast Neoplasms 6 Triple Negative Breast Neoplasms 5 Small Cell Lung Carcinoma 5 Skin Neoplasms 4 Ovarian Neoplasms 4 Kidney Neoplasms 4 Hodgkin Disease 4 Glioblastoma 4 Advanced Cancer 4 Prostatic Neoplasms 3 Myelodysplastic Syndromes 3 Lymphoma, Non-Hodgkin 3 Lymphoma 3 Liver Neoplasms 3 Hematologic Neoplasms 3 Fallopian Tube Neoplasms 3

Interventions

pembrolizumab 1 durvalumab 1 atezolizumab 1 S-Adenosylmethionine 1 Nivolumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03721679 2021-02-01

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Oncovir, Inc.

Phase 1/2 Terminated

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡